Risk Factors Associated With the Progression of Adenomyosis
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Dec 1, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying adenomyosis, a common condition in women that can cause pelvic pain and heavy bleeding. The researchers want to understand how adenomyosis progresses over time and what factors might influence this progression. They will use a type of ultrasound called transvaginal ultrasound to look for signs of the condition in participants.
Women aged 18 to 55 who have specific signs of adenomyosis may be eligible to join the study. However, those who have had a hysterectomy, are virgins, have had recent pregnancies, or have certain cancers cannot participate. If you join the trial, you will help researchers learn more about adenomyosis, which could lead to better treatments in the future. Your participation will involve some tests, and you'll be informed about everything you need to know along the way.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients aged between 18 and 55 years;
- • Presence of at least two direct and indirect signs according to the MUSA classification
- • Obtaining informed consent
- Exclusion Criteria:
- • Patients undergoing hysterectomy;
- • Virgo patients;
- • Patients reporting intolerance to transvaginal ultrasound;
- • Gynaecological oncology;
- • Recent pregnancy or childbirth (within 6 months)
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Paolo Casadio, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported